| Cardiovascular Risk Management |
1 |
1 |
| Breast Cancer |
0 |
0.88 |
| Biologic Therapy |
0 |
0.8 |
| Toxicology |
0 |
0.99 |
| Cancer |
0 |
0.76 |
| Targeted Cancer Therapy |
0 |
0.64 |
| Antineoplastic Drug |
0 |
0.57 |
| Cancer Survivor |
0 |
0.56 |
| Clinical Guidelines |
0 |
0.49 |
| HER2-Positive Breast Cancer |
0 |
0.47 |
| Heart Failure (HF) |
0 |
0.43 |
| Hypertension |
0 |
0.4 |
| Arrhythmia |
0 |
0.37 |
| Coronary Artery Disease (CAD) |
0 |
0.35 |
| Cardiomyopathy |
0 |
0.27 |
| Heart |
0 |
0.24 |
| Atrial Fibrillation |
0 |
0.22 |
| Cardiovascular Imaging |
0 |
0.22 |
| Cardiovascular disease |
0 |
0.19 |
| Europe |
0 |
0.14 |
| Myocardial Infarction (MI) |
0 |
0.1 |
| Hematology |
0 |
0.08 |
| Radiation Therapy |
0 |
0.08 |
| Acute Myocardial Infarction (MI) |
0 |
0.06 |
| Anaplastic Lymphoma Kinase |
0 |
0.06 |
| Anthracyclines |
0 |
0.06 |
| Chemotherapy |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Infarction |
0 |
0.06 |
| Myocarditis |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Viral Myocarditis |
0 |
0.06 |
| Humanized Monoclonal Antibody |
0 |
0.05 |
| ALK Inhibitor |
0 |
0.04 |
| Angiotensin II Receptor Blockade |
0 |
0.04 |
| CAR-T |
0 |
0.04 |
| ACE Inhibitor |
0 |
0.03 |
| Adverse Effects |
0 |
0.03 |
| Artery |
0 |
0.03 |
| Beta-Adrenergic Agonist |
0 |
0.03 |
| Breast |
0 |
0.03 |
| Cardiotoxicity |
0 |
0.03 |
| Drug Interaction |
0 |
0.03 |
| Echocardiography |
0 |
0.03 |
| Endocrine Therapy |
0 |
0.03 |
| Health Education and Counseling |
0 |
0.03 |
| Impairment |
0 |
0.03 |
| Lipids Management |
0 |
0.03 |
| Lung |
0 |
0.03 |
| Monoclonal Antibody |
0 |
0.03 |
| Obesity |
0 |
0.03 |
| Pregnancy |
0 |
0.03 |
| Prognosis |
0 |
0.03 |
| Radiation Exposure |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Referral |
0 |
0.03 |
| Shared Decision-Making |
0 |
0.03 |
| Spain |
0 |
0.03 |
| Statins |
0 |
0.03 |
| Tumor |
0 |
0.03 |
| Tyrosine Kinase |
0 |
0.03 |
| Vascular Endothelial Growth Factor |
0 |
0.03 |